Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773755 | 0.83 | MEN1 (0.42) | P2RX7SMN1; SMN2KDM4ELMNANPSR1 | |
| SCHEMBL21218907 | 0.78 | MEN1 (0.51) | P2RX7LMNAKMT2AMEN1AR | |
| SCHEMBL3776919 | 0.73 | P2RX7 (0.43) | P2RX7LMNAKMT2AMEN1PTGS1 | |
| SCHEMBL3769291 | 0.72 | P2RX7 (0.40) | P2RX7LMNAKMT2AMEN1 | |
| SCHEMBL3767468 | 0.71 | P2RX7 (0.54) | P2RX7LMNAKMT2AMEN1PTGS1 | |
| SCHEMBL21548891 | 0.71 | SMN1; SMN2 (0.73) | P2RX7SMN1; SMN2HTTKDM4EL3MBTL1 | |
| SCHEMBL9479565 | 0.70 | SMN1; SMN2 (0.50) | P2RX7SMN1; SMN2HTTKDM4EL3MBTL1 | |
| SCHEMBL3779266 | 0.70 | ALDH1A1 (0.42) | P2RX7SMN1; SMN2KDM4ELMNANPSR1 | |
| SCHEMBL3403485 | 0.69 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL2097653 | 0.69 | IDO1 (0.65) | SMN1; SMN2HTTKDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-1572708-B1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1572708-A1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004052903-A1 | NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261664-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | UGGT1, SLC5A2, SLC5A1 | P2RX7 448/4885SMN1; SMN2 4791/4885HTT 3013/4885 |
| US-20040259819-A1 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | SLC5A1, UGGT1, SLC5A2 | P2RX7 478/4885SMN1; SMN2 4794/4885HTT 3443/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | P2RX7 1525/4885SMN1; SMN2 3099/4885HTT 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.